- ̍̍ CSE: BRAX
- ̍̍ OTC: BRAXF
- ̍̍ FWB: 4960
Search upcoming and past events
- This event has passed.
BRAXIA SCIENTIFIC ANNOUNCES PARTICIPATION AT PSYCH INVESTOR SUMMIT ON JULY 7, 2021
July 7, 2021 - July 9, 2021
See full press release
TORONTO, ONTARIO July 6, 2021 – Braxia Scientific Corp. (“Braxia”, or the “Company”), (CSE: BRAX) (OTC: BRAXF) (FWB: 496), a medical research company with clinics providing innovative ketamine treatments for persons with depression and related disorders, is pleased to announce its participation at the upcoming PSYCH Investor Summit: Research & Development. The conference will be held virtually on July 7, 2021.
Braxia CEO Dr. Roger McIntyre will deliver a presentation discussing the recently announced funding by the Canadian Institutes Of Health Research (CIHR), of the Government of Canada, to support the first of its kind Ketamine clinical trial for Bipolar Depression.
Additionally, Dr. McIntyre will discuss Braxia’s initiatives related to developing innovative therapeutics and delivery systems, while also administering patient care in its growing network of clinics. The presentation will be followed by a Q&A.
Dr. McIntyre will also take part in a panel discussion, along with Canadian Securities Exchange CEO Richard Carleton, on “The Next 5-10 Years of Research & Development.”